文献速递中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

含戊二醛产品的急性中毒:临床特征与结局

Poisoning of glutaraldehyde-containing products: clinical characteristics and outcomes.
PubMed 文献 · Clin Toxicol (Phila) · 2020-10-28
一句话结论含戊二醛产品中毒多为农场消毒剂意外经口暴露,表现以局部刺激为主,但出现神经系统症状或AKI者死亡风险升高,需密切监测与积极治疗。

该研究为5年回顾性队列研究(2013年7月至2018年6月),基于Ramathibodi中毒中心数据,纳入244例含戊二醛产品中毒病例。产品99.2%为农场消毒剂,中位浓度15%,76.2%含阳离子去污剂和甲醛等辅料。暴露途径95.0%为经口摄入,56.9%为意外,其余为自杀企图(1例皮下注射)。61.1%出现全身症状,23例(9.4%)出现腐蚀性损伤,病死率3.7%。多因素分析显示就诊时神经系统症状或AKI与死亡相关。

要点

  • 含戊二醛产品中毒以农场消毒剂经口意外暴露为主(99.2%为农场消毒剂,95.0%经口),多数表现为轻度局部刺激症状。
  • 23例(9.4%)出现腐蚀性损伤,经口摄入的局部损伤较其他途径更严重,需评估消化道腐蚀风险。
  • 149例(61.1%)出现全身症状,包括生命体征异常、血氧饱和度下降、意识改变、电解质紊乱、代谢性酸中毒、AKI、肝炎和横纹肌溶解。
  • 病死率3.7%;多因素分析显示就诊时神经系统症状或AKI与死亡相关,应作为重点筛查指标。
  • 1例皮下注射者出现局部及全身效应但存活,提示非经口途径也需警惕全身毒性。

适用人群与场景

  • 本研究纳入2013年7月至2018年6月Ramathibodi中毒中心记录的含戊二醛产品中毒病例,共244例,多为男性,中位年龄37岁。
  • 暴露产品99.2%为农场消毒剂,中位浓度15%,76.2%含阳离子去污剂和甲醛等辅料。
  • 95.0%为经口摄入;56.9%为意外暴露,其余为自杀企图经口摄入,另1例为故意皮下注射。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 多数患者病情轻度,仅接受支持治疗并完全康复;中位住院时间2天。
  • 原文建议:因神经系统症状或AKI可预测死亡,医生应在含戊二醛暴露患者就诊时寻找这些因素,以进行密切监测和积极治疗。

红旗征与不能漏的情况

  • 就诊时出现神经系统症状与死亡相关,需密切监测和积极治疗。
  • 就诊时出现急性肾损伤(AKI)与死亡相关,需密切监测和积极治疗。
  • 经口摄入可导致腐蚀性损伤(23例,9.4%),局部效应较其他途径更严重。
  • 全身效应包括生命体征异常、血氧饱和度下降、意识改变、高/低钠血症、低钾血症、低碳酸氢盐/代谢性酸中毒、AKI、肝炎和横纹肌溶解,多由经口摄入引起。

研究设计与关键结果

  • 研究类型:5年回顾性队列研究(2013年7月至2018年6月),使用Ramathibodi中毒中心数据,样本量244例。
  • 人群:含戊二醛产品中毒病例,多为男性,中位年龄37岁;产品99.2%为农场消毒剂,中位浓度15%,76.2%含阳离子去污剂和甲醛等辅料。
  • 暴露特征:95.0%经口摄入;56.9%为意外,其余为自杀企图经口摄入,另1例为故意皮下注射。
  • 主要结局:病死率3.7%;23例(9.4%)出现腐蚀性损伤;149例(61.1%)出现全身症状;多数患者病情轻度,仅接受支持治疗并完全康复,中位住院时间2天。
  • 多因素分析:就诊时神经系统症状或AKI与死亡相关。
  • 1例皮下注射者出现局部及全身效应但存活。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(原文自述为5-year retrospective cohort study)。
  • 局限性:原文未述局限性。

对床旁实践的改变

  • 对含戊二醛产品暴露患者,就诊时应主动筛查神经系统症状和AKI,因其与死亡相关,需密切监测和积极治疗。
  • 经口摄入者应评估腐蚀性损伤风险,其局部效应较其他途径更严重。
  • 多数患者仅需支持治疗即可完全康复,但出现全身效应(如生命体征异常、血氧饱和度下降、意识改变、电解质紊乱、代谢性酸中毒、肝炎、横纹肌溶解)者需积极处理。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: This study describes the clinical characteristics, outcomes, and factors at presentation associated with death of cases poisoned by glutaraldehyde (GA)-containing products.

METHODS: We performed a 5-year retrospective cohort study (July 2013-June 2018) using data from the Ramathibodi Poison Center.

RESULTS: There were 244 cases included in this study. Most were men with a median age of 37 years. The GA-containing products were mainly used as farm disinfectants (99.2%), with a median concentration of 15%. Most products (76.2%) contained co-formulants such as cationic detergents and formaldehyde.Most circumstances were accidental (56.9%). The others were suicide attempts by ingestion, except one patient who intentionally injected GA subcutaneously. The most common route of exposure was ingestion (95.0%). Local symptoms in areas of exposure were common. Ingestion resulted in more severe local effects than other routes, and corrosive effects occurred in 23 cases (9.4%). Systemic signs and symptoms occurred in 149 patients (61.1%). Systemic effects included abnormal vital signs, desaturation, altered mental status, hypo/hypernatremia, hypokalemia, low bicarbonate/metabolic acidosis, acute kidney injury (AKI), hepatitis, and rhabdomyolysis. Systemic effects mostly resulted from ingestion. Most patients had mild severity, received only supportive treatment, and fully recovered. The median length of hospital stay was 2 days. The one case of subcutaneous injection developed both local and systemic effects but survived. The mortality rate was 3.7%. Multivariate analysis indicated that either neurological symptoms or AKI at presentation were associated with death.

CONCLUSIONS: In our study, patients were exposed to GA-containing products that were mainly used as farm disinfectants and were generally co-formulated with other substances. Poisoning with these products commonly resulted in mild local irritative symptoms. However, some cases developed corrosive symptoms, systemic effects, or even died. As neurological symptoms or AKI could prognosticate deaths; physicians should look for these factors in patients with GA exposure at presentation for close monitoring and aggressive treatment.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Thumtecho S, Sriapha C, Tongpoo A, et al. Poisoning of glutaraldehyde-containing products: clinical characteristics and outcomes. Clin Toxicol (Phila). 2020. PMID: 33112670. doi:10.1080/15563650.2020.1832231

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。